CANONSBURG, Pa. (AP) — Mylan Inc. said today it has received FDA approval for a generic version of the Astellas Pharma
drug Prograf, which is used to prevent rejection of transplanted organs.
Mylan received approval for 0.5-, 1- and 5-milligram versions of its
Tacrolimus Capsules. It will launch the drug immediately.
Prograf is used to suppress the immune system and prevent the rejection of
transplanted livers, kidneys, and hearts. In July, Watson Pharmaceuticals Inc. also received approval to sell a generic
version of the drug.
